Criterios clínicos y de laboratorio para el uso de los inhibidores SGLT2 en la enfermedad renal crónica.

Chronic kidney disease (CKD) is characterized by a sustained reduction in glomerular filtration rate (GFR) and/or by markers of kidney damage. Sodium-glucose cotransporter type 2 inhibitors (SGLT2i) have shown renoprotective effects by inducing glycosuria through the inhibition of glucose reabsorption in the proximal tubule. This research aimed to identify clinical and laboratory criteria for their use in CKD patients through a systematic review of scientific literature published between 2020 and 2025. The results show that in Ecuador, males over 50 years of age with type 2 diabetes and hypertension are the most affected. It was identified that patients with a GFR greater than 20 ml/min/1.73 m² and a urinary albumin-to-creatinine ratio (UACR) above 300 mg/g can benefit from SGLT2i treatment, even in the absence of diabetes. Additionally, in patients with normal urine output, these drugs are considered safer, as they reduce the risk of urinary tract infections. However, it is recommended to adjust diuretic and antihypertensive doses in euvolemic patients and to delay the initiation of SGLT2i in cases of hypovolemia or hypotension. Finally, the need to implement public policies that ensure the availability of these medications at the primary care level is emphasized, in order to prevent CKD progression and reduce the burden on dialysis services

• Autore principale: Caisatoa Cabrera, Estefanía Dayana (author)
• Altri autori: Carvajal Trujillo, Valeria Michelle (author)
• Natura: bachelorThesis
• Lingua: spa
• Pubblicazione: 2025
• Soggetti: Enfermedad renal crónica; iSGLT2; Tasa de filtración glomerular; Albuminuria
• Accesso online: http://dspace.unach.edu.ec/handle/51000/15643